Crossref
Fidaxomicin: novel antibiotic for Clostridium difficile infection
Prescriber · 2013
DOI: 10.1002/psb.1002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prescriber, 2013. Verfasst von Steve Chaplin und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Fidaxomicin (Dificlir) is a new antibiotic licensed for the treatment of C. difficile infection in adults. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Mark Wilcox discusses its place in treatment.
Zitieren
APA
Chaplin, S., & Wilcox, M. (2013). Fidaxomicin: novel antibiotic for Clostridium difficile infection. Prescriber. https://doi.org/10.1002/psb.1002
Vancouver
Chaplin S, Wilcox M. Fidaxomicin: novel antibiotic for Clostridium difficile infection. Prescriber. 2013. doi:10.1002/psb.1002
BibTeX
@article{Chaplin2013,
author = {Chaplin, Steve and Wilcox, Mark},
title = {Fidaxomicin: novel antibiotic for Clostridium difficile infection},
journal = {Prescriber},
year = {2013},
doi = {10.1002/psb.1002}
}
EUVIMED